<DOC>
	<DOCNO>NCT00097487</DOCNO>
	<brief_summary>This study Phase IV , prospective , nonrandomized , community-based study clinical outcome patient metastatic breast cancer treat Herceptin taxane .</brief_summary>
	<brief_title>A Study Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin Taxane</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Signed informed consent Available tissue central laboratory evaluation HER2 status Histologically confirm , measurable nonmeasurable evaluable , HER2 positive metastatic breast cancer ( HER2 positive define 3+ stain IHC gene amplification FISH , determine local central laboratory ) Life expectancy &gt; 6 month Female , age &gt; =18 year ECOG performance status 0 , 1 , 2 Adequate bone marrow function indicate follow : *ANC &gt; 1500/uL , *Platelet count &gt; =100,000/uL Adequate renal function , indicate creatinine &lt; =1.5× upper limit normal ( ULN ) Adequate liver function , indicate bilirubin &lt; =1.5× ULN AST ALT &lt; 2× ULN unless related primary disease Use adequate mean birth control ( woman childbearing potential ) Initiation Herceptin &gt; =4 week begin taxane chemotherapy Prior chemotherapy metastatic disease Prior cumulative anthracycline dose &gt; 360 mg/m2 History significant cardiac disease uncontrolled arrhythmias Ejection fraction &lt; 50 % low limit normal Active infection Symptomatic untreated brain metastasis Pregnancy lactation Concomitant malignancies previous malignancy within last 5 year , exception adequately treat basal squamous cell carcinoma skin carcinoma situ cervix Symptomatic intrinsic lung disease extensive tumor involvement lung , result dyspnea rest Hypersensitivity study medication Major organ failure systemic disease preclude safe administration study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>